A Proof of concept study with 0.5% Roflumilast cream in patients with mild to moderate plaque Psoriasis

Study identifier:RO-2351-002-EM

ClinicalTrials.gov identifier:NCT00746434

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A proof of concept study with 0.5% Roflumilast cream in patients with mild to moderate plaque Psoriasis

Medical condition

Plaque psoriasis

Phase

Phase 2

Healthy volunteers

No

Study drug

Roflumilast cream, Placebo cream

Sex

All

Actual Enrollment

0

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2008
Estimated Primary Completion Date: 01 Jun 2009
Estimated Study Completion Date: 01 Sept 2009

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Nycomed US Inc.

Inclusion and exclusion criteria